Inhalis Therapeutics, a specialist in the area of inhalable therapies based in Lugano in the canton of Ticino, has filed a patent application for its lead asset INHAL-101, further details of which can be found in a press release. “This ground-breaking formulation employs proprietary mSAS supercritical fluid technology”, comments Silvia Panigone, CEO of Inhalis Therapeutics. The company’s aim is to use INHAL-101 to selectively inhibit the IPF-driven pathogenic elements. “This recent patent application strengthens our competitive positioning and provides additional value for Inhalis”, she adds.
Inhalis Therapeutics is planning to launch a clinical trial of INHAL-101 in the fourth quarter of next year. In addition to its active ingredient to treat IPF, the company’s portfolio also includes a drug aimed at combating lung cancer, as well as other compounds that are currently subject to preclinical efficacy studies in oncology, fibrotic diseases and pulmonary infections. ce/hs
Related news
Meet with an expansion expert
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line.